NCT01697540

Brief Summary

  1. 1.Written informed consent must be obtained before any study specific procedures are undertaken.
  2. 2.The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

September 28, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 2, 2012

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 27, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 27, 2017

Completed
Last Updated

August 9, 2018

Status Verified

January 1, 2017

Enrollment Period

4.8 years

First QC Date

September 28, 2012

Last Update Submit

August 8, 2018

Conditions

HIV

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HIV/AIDS group

You may qualify if:

  • HIV-infected patients who receive HAART therapy but have metabolic side effects.
  • Age over 20 years old

You may not qualify if:

  • Abnormal liver function: GOT or GPT 5 times over normal upper limit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tropical medicine center

Kaohsiung City, Taiwan

Location

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 28, 2012

First Posted

October 2, 2012

Study Start

September 1, 2012

Primary Completion

June 27, 2017

Study Completion

June 27, 2017

Last Updated

August 9, 2018

Record last verified: 2017-01

Locations

TW(1)